DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Methotrexate for Central Serous Chorioretinopathy Treatment Trial

Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Central Serous Chorioretinopathy

Intervention: Methotrexate (Drug); Delayed treatment (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Edward Averbukh

Official(s) and/or principal investigator(s):
Edward Averbukh, MD, Principal Investigator, Affiliation: Hadassah Medical Organization

Summary

Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Clinical Details

Official title: Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Optical Coherence Tomography indicating the level of central serous detachment

Detailed description: Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the center of the macula in adults of working age. Though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few short retrospective series of beneficial effect of MTX on CSC were reported recently. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision in a prospective manner.

Eligibility

Minimum age: 20 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Central Serous Chorioretinopathy

Exclusion Criteria:

- Pregnancy

- Liver disease

- Kidney disease

- Steroid use

Locations and Contacts

Hadassah Hebrew Univercity Medical Center, Jerusalem 91120, Israel; Not yet recruiting
Edward Averbukh, MD, Phone: +972-508946140, Email: edwaver@gmail.com
Samer Khateb, MD, PhD, Phone: +972-542504857, Email: samerkhateb@gmail.com
Samer Khateb, MD, PhD, Principal Investigator
Additional Information

Starting date: August 2012
Last updated: July 18, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017